Graphene Oxide Based Theranostic Platform forT1-Weighted Magnetic Resonance Imaging and Drug Delivery
Citations Over TimeTop 10% of 2013 papers
Abstract
Magnetic resonance imaging (MRI) is a powerful and widely used clinical technique in cancer diagnosis. MRI contrast agents (CAs) are often used to improve the quality of MRI-based diagnosis. In this work, we developed a positive T1 MRI CA based on graphene oxide (GO)-gadolinium (Gd) complexes. In our strategy, diethylenetriaminepentaacetic acid (DTPA) is chemically conjugated to GO, followed by Gd(III) complexation, to form a T1 MRI CA (GO-DTPA-Gd). We have demonstrated that the GO-DTPA-Gd system significantly improves MRI T1 relaxivity and leads to a better cellular MRI contrast effect than Magnevist, a commercially used CA. Next, an anticancer drug, doxorubicin (DOX), was loaded on the surface of GO sheets via physisorption. Thus-prepared GO-DTPA-Gd/DOX shows significant cytotoxicity to the cancer cells (HepG2). This work provides a novel strategy to build a GO-based theranostic nanoplatform with T1-weighted MRI, fluorescence imaging, and drug delivery functionalities.
Related Papers
- → Design and synthesis of novel DOTA(Gd3+)–polymer conjugates as potential MRI contrast agents(2011)31 cited
- → Binding of a dimeric manganese porphyrin to serum albumin: towards a gadolinium-free blood-pool T 1 MRI contrast agent(2014)27 cited
- → Block Copolymer-Based Gadolinium Nanoparticles as MRI Contrast Agents with High T 1 Relaxivity(2012)21 cited
- → A self-assembly heterotrinuclear gadolinium(III)–iron(II) complex as a MRI contrast agent(2011)13 cited
- Relaxivities of Gadolinium Heteropoly Complexes in Aqueous Solution for MRI Contrast Agent(2000)